EMBC - embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes | Benzinga
PARSIPPANY, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced its sponsorship of a symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference. This event is scheduled for Wednesday, March 6, at 10:40 a.m. Eastern Standard Time / 14:40 Central European Time. Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.
Entitled "Unlocking the potential of insulin pumps for personalized T2D care," the symposium aims to highlight the significance of insulin pump therapy among the extensive treatment options available for type 2 diabetes (T2D). Through a series of presentations and a panel discussion led by distinguished faculty, participants will gain insight into clinical considerations for initiating insulin pump therapy, including selection of the most suitable pump.
"We are thrilled to support this symposium as part of our ongoing commitment to fostering innovation and improving care for individuals with type 2 diabetes," said Henry Anhalt, D.O., Chief Medical Officer, embecta. "We believe this event will greatly contribute to the enhancement of informed decision-making regarding insulin pump therapy among patients,"
The symposium will be chaired by Natalie J. Bellini, DNP, FNP-BC, BC-ADM, CDCES, Clinical Assistant Professor of Medicine, ...